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The transcription factor NF-E2-related factor 2 (Nrf2) induces cytoprotective genes, but has
also been linked to the regulation of hepatic energy metabolism. In order to assess the
pharmacological potential of hepatic Nrf2 activation in metabolic disease, Nrf2 was acti-
vated over 7 weeks in mice on Western diet using two different siRNAs against kelch-like
ECH-associated protein 1 (Keap1), the inhibitory protein of Nrf2. Whole genome expres-
sion analysis followed by pathway analysis demonstrated successful knock-down of Keap1
expression and induction of Nrf2-dependent genes involved in anti-oxidative stress defense
and biotransformation, proving the activation of Nrf2 by the siRNAs against Keap1. Neither
the expression of fatty acid- nor carbohydrate-handling proteins was regulated by Keap1
knock-down. Metabolic profiling of the animals did also not show effects on plasma and
hepatic lipids, energy expenditure or glucose tolerance. The data indicate that hepatic
Keap1/Nrf2 is not a major regulator of glucose or lipid metabolism in mice.
Introduction
The transcription factor NF-E2-related factor 2 (Nrf2) regulates the expression of several cyto-
protective genes and is a promising target for the treatment of chronic, oxidative stress–related
disorders, such as neurodegenerative diseases and chronic kidney disease [1–3]. Nrf2 is regu-
lated by the kelch-like ECH-associated protein 1 (Keap1). Keap1 acts as a sensor for oxidative
and electrophilic stress. Without stressors, Keap1 mediates the ubiquitinylation and subse-
quent proteolytic degradation of Nrf2. In the presence of oxidative or electrophilic stress, cyste-
ine residues within Keap1 becomemodified,which prevents the degradation of Nrf2. Nrf2
subsequently accumulates in the nucleus, where it regulates the expression of several antioxida-
tive and anti-inflammatory proteins by binding to the cis-acting antioxidant response element
within gene promoters.
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Nrf2 activation has also been linked to the regulation of intermediarymetabolism and could
therefore be a promising approach for the treatment of steatosis, as well as insulin resistance.
[3–5]. Evidence for this derives from studies using pharmacological activators of Nrf2 such as
CDDO-Im, CDDO-Me and Oltipraz. Here, a reduction of obesity and hepatic lipids and an
improvement of glucose tolerance were observed in rodent models [6–8]. However, these mol-
ecules are associated with toxic effects, which could have been a considerable confounding fac-
tor in the metabolic studies [9, 10]. Geneticmodels leading to either a loss-of- or gain-of-Nrf2
function gave no clear picture about the role of Nrf2 in hepatic lipid and carbohydrate metabo-
lism [11–20]. With that it is unclear, whether the activation of Nrf2 has a reasonable therapeu-
tic potential to prevent dysregulation of lipid and carbohydrate metabolism under unfavorable
environmental conditions as reflected by a Western diet. In the present study we assessed the
effects of inducible Nrf2 activation in the hepatic metabolism of adult mice under a Western
diet. Due to the lack of suitable pharmacological tool compounds [21], we activated Nrf2 in
liver using siRNAs against Keap1 as recently described [22]. Our data suggest that the chronic




All chemicals were purchased from Sigma-Aldrich (Munich, Germany), Merck (Darmstadt,
Germany) or Roth (Karlsruhe, Germany), reagents for RNA, cDNA and qPCR from Thermo
Scientific (Schwerte, Germany) or Qiagen (Hilden, Germany) unless stated otherwise.
Animal studies
All animal experiments were performed in accordance with the terms of the German Animal
Protection Law, as well as according to international animal welfare legislation and institu-
tional ethical guidelines of the Charité Berlin, Germany, and were approved by the Landesamt
für Gesundheit und Soziales (Approval number G 0175/13, LAGeSo Berlin, Germany).
In our chronic siRNA study, 8-week-oldmale C57BL6/J mice (Forschungseinrichtungen für
experimentelleMedizin, Charité Berlin, Germany) were fed ad libitum aWestern diet (WD)
consisting of a high-fat diet (60% kcal from fat, D12492 (I), Ssniff Spezialdiäten, Soest, Ger-
many) supplemented with 6% sucrose in the water for 7 weeks to induce insulin resistance and
hepatic lipid accumulation.
In the first in vivo pilot study 8-week-oldmale C57BL6/J mice were fed a normal chow diet
(ND) and were injected for 2, 4 or 6 days with 1 mg per kg body weight of either siRNA
(siKeap1-1, siKeap1-2 and siControl) to assess efficacy and duration of siRNA action. In the
second in vivo pilot study 8-week-oldmale C57BL6/J mice were fed a ND or a WD for 20
weeks.
All mice were maintained in individually ventilated cages (max. 5 per cage) in an environ-
mentally controlled room with a 12 h light-dark cycle. Body weight was monitored weekly. For
the siRNA intervention, mice were divided into three groups with equal body weight and fat
mass. Each group was injectedweekly with 1 mg modified siRNA per kg body weight in PBS of
liver-selective Keap1-specific siRNA (group 1: siKeap1-1, group 2: siKeap1-2) or unspecific
scrambled control siRNA (group 3: siControl) via the tail vein for 7 weeks. Body composition
(BC) was assessed by 1H magnetic resonance spectroscopy using a Minispec LF50 Body Com-
position Analyzer (Bruker BioSpin, Billerica, USA) before starting the intervention, metabolic
cage analysis (MCA) and sacrificing (Ex). Isoflurane inhalation (1.5%) was used for anesthesia
during operation and mice were sacrificedby cervical dislocation.
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Glucose tolerance test (ipGTT). Mice were fasted overnight and basal blood glucose was
measured before injecting an intraperitoneal glucose bolus of 1 g/kg body weight. Blood glu-
cose was measured subsequently at 0, 15, 30, 60 and 120 min.
Activity and calorimetricanalysis. Various phenotypic parameters were assessed in met-
abolic cages with a TSE LabMaster System (TSE Systems, Bad Homburg, Germany). Mice were
acclimated to special water bottles for 24 h and to the metabolic cages for 16 h before starting
the measurements. Mice were supplied withWD, individually housed and data on gas
exchanges, activity, and food/liquid intake were collected for 48 h. Calorimetrywas performed
with a computer-controlled open circuit calorimetry system composed of 10 metabolic/respira-
tory cages. Each cage was equipped with a special water bottle and a food tray connected to a
balance as well as an activity monitor. Oxygen consumption and carbon dioxide production
were measured for each mouse at 3 min intervals and respiratory quotient (RQ) was calculated
as the ratio of CO2 production to O2 consumption. O2 consumption, CO2 production, energy
expenditure (EE) and caloric intake were adjusted for lean bodymass from the body composi-
tion measurements [23]. Data collected after 48 h were analyzed as (daily) average.
siRNA Preparation
Synthesis, purification and formulation of liver-selectiveKeap1-specific siRNAs. RNA
oligonucleotides were synthesized at a scale of 1 μmol (in vitro) or 10 μmol (in vivo) on an ABI
394 DNA/RNA or BioAutomation MerMade 12 synthesizer using commercially available 50-
O-DMT-30-O-(2-cyanoethyl-N,N-diisopropyl) phosphoramidite monomers (SAFC) of uri-
dine, 4-N-acetylcytidine (CAc), 6-N-benzoyladenosine (ABz) and 2-N-isobutyrylguanosine
(GiBu) with 20-O-TBDMS protection or 2’-OMe modification and 50-O-DMT-thymidine-30-
O-(2-cyanoethyl-N,N-diisopropyl) phosphoramidite (dT) following standard protocols for
solid-phase synthesis and deprotection [24, 25]. The crude oligonucleotides were analyzed by
IEX and LC–MS and purified by anion-exchange high-performance liquid chromatography
(IEX) using a linear gradient of 10–50% buffer B in 30min. Solutions of 0.02 M Na2HPO4 (pH
11) and 0.02 M Na2HPO4/1 M NaBr (pH 11) were used as eluents A and B, respectively. To
ensure high fidelity of the data, all single strands were HPLC purified to> 85% purity. The
purity and identity of the oligonucleotides was confirmed by ion-exchange chromatography
and LC–MS, respectively. For the cell culture experiments, 100 μM stock solutions of siRNA in
PBS were prepared by mixing equimolar amounts of complementary sense and antisense
strands in 1x PBS buffer and heating the solution to 90°C for 10 min and allowing it to cool
slowly to room temperature to complete the annealing process. siRNAs were further character-
ized by HPLC and were stored frozen until use. Sequences of the unmodified siRNAs directed
against murine Keap1 mRNA (siKeap1-1 and siKeap1-2) and non-silencing scrambled control
siRNA (siControl) are depicted in Table 1.
Table 1. Sequences of siRNA molecules used in this study.
siRNA Sequence
siControl 5’-UUU CGC GUA UAC GCG AAA C dTdT-3’
siControl sense 5’-AUC GUA CGU ACC GUC GUA U dTdT-3’
siControl antisense 5’-AUA CGA CGG UAC GUA CGA U dTdT-3’
siKeap1-1 sense 5’-GCG CCA AUG UUG ACA CGG A dTsdT-3’
siKeap1-1 antisense 5’-UCC GUG UCA ACA UUG GCG C dTsdT-3’
siKeap1-2 sense 5’-CCU GCA ACU CGG UGA UCA A dTsdT-3’
siKeap1-2 antisense 5’-UUG AUC ACC GAG UUG CAG G dAsdA-3’
Capital letters: RNA; d: DNA.
doi:10.1371/journal.pone.0166110.t001
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Large scale RNA oligonucleotide synthesis for in vivo administration was carried out by Bio-
spring (Frankfurt, Germany). Formulation of siRNA for delivery to mouse liver tissue in vivo
was performed in lipid nanoparticles (LNPs) based on the Axolabs’ proprietary cationic lipid
XL-10 (Axolabs, Kulmbach, Germany).
siRNA stability in mouse serum. Primary and modified siRNAs were tested for nuclease
stability in 50%mouse serum. For this 160 μl of 2.5 μM siRNA in 1x DPBS and 160 μl mouse
serum (Sigma) were incubated at 37°C for 0, 0.5, 2, 4, 6, 8 and 24 h. At each time-point 20 μl of
the reactionmixture was removed and quenched with a stop solution (Lysis Solution, Protein-
ase K, water) at 65°C for 30 min. prior to HPLC analysis on a Waters 2695 SeparationModule
and a 2487 Dual Absorbance Detector, RNase-free water was added to each sample. The solu-
tion was analyzed by HPLC using a DNAPac PA200 analytical column (Thermo Scientific).
Serumhalf-lives were estimated for both strands of the siRNAs and are shown in Table 2.
Immune stimulatory potential of siRNA. Immuno-stimulative potential of siRNA was
measured by secretion of IFNα from freshly isolated and transfected human peripheral blood
mononuclear cells (PBMC). PBMCs were isolated from approx. 16 ml blood of three healthy
donors that was collected in Vacutainer tubes coated with sodium heparin (BD, Heidelberg,
Germany) according to the manufacturer’s instructions. Subsequently, 100 nM siRNA was
reverse transfected into 100,000 PBMCs with 0.3 μl Lipofectamine 2000 per 96-well (n = 2) in a
total volume of 150 μl serum-freeRPMI medium for 24 h. Single-strandedRNA (“R-0006”)
and DNA (“CpG ODN”) oligonucleotides were applied as positive controls. 25 μl of the super-
natant was used for measurement of IFNα concentration using a self-established electrochemi-
luminescence assay based on MesoScale Discovery’s (MSD, Rockville,USA) technology. IFNα
values are shown in Table 2.
siRNA transfection and in vitro validation. Hepa1c1c7 cells were reversely transfected
with siRNAs using Lipofectamine RNAiMAX (Thermo Scientific) according to the manufac-
turer’s instructions. To avoid variations in the transfection efficiencywhen transfecting very
low amounts for IC50 curves, 10 nM of non-targeting control (siControl) were used in each
transfectionmix. The transfectionwas performed in 96-well plates adding 12,000 cells/well. 48
h post-transfection, RNA was isolated with the SV96 Total RNA isolation system and gene
expression was analyzed as described, previously [26].
Cytotoxicity assay. Hepa1c1c7 mouse hepatoma cells were reversely transfected with siR-
NAs using LipofectamineRNAiMAX according to the manufacturer’s instructions in 96-well
plates. 72 h post-transfection, cell viability was analyzed with the ViaLight™ Plus Cell
Table 2. Chemical modification of Keap1-specific siRNAs improved their pharmacokinetic properties.
siRNA siKeap1-1 siKeap1-1* siKeap1-2 siKeap1-2*
(186.1) (190.2) (191.1) (185.4)
IC50KD (nM) 0.14 0.25 0.61 0.02
ImaxKD (%) 96 91 97 94
Serum stability (h): > 4 > 8 2 4
t1/2 in 50% mouse serum
Cytotoxicity (%): 85 96 89 89
Viability of Hepa1c1c7 cells
Immune stimulation (pg/ml): 423 221 523 144
IFNα release PBMCs
ImaxKD: maximal knockdown of Keap1 mRNA expression
* modified siRNA.
doi:10.1371/journal.pone.0166110.t002
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Proliferation and Cytotoxicity BioAssay Kit (Lonza, Cologne,Germany). Cytotoxicity was
assessed in relation to the non-transfected control cells set at 100% (Table 2).
Biochemical analysis
Plasma glucose levels of mice were determined by measuring at least in duplicate ( 10% dis-
crepancy) using Contour XT glucometer (Bayer Vital, Leverkusen,Germany). Plasma lipid
measurements were carried out with a Cobas 6000 c501 module (Roche/Hitachi) using the cor-
responding Cobas substrate kits according to the manufacturer’s instructions. Liver lipids were
analyzed after lipid extraction described elsewhere [27, 28], with an AU680 Analyzer (Beckman
Coulter/Olympus, Krefeld, Germany) and the corresponding kits. As an exception, phospho-
lipids in serum and liver tissue were measured with a Phospholipid kit from DiaSys (Holzheim,
Germany). Liver transaminases (AST, ALT) were measured in serum after the siRNA treat-
ment. Liver glycogen content was measured on a xMark Microplate absorbance spectropho-
tometer (Bio-Rad, Hercules, USA) according to the method from bio-protocol [29].
Histochemistry
Liver slices were snap-frozen, embedded in Tissue-Tek (O.C.T. Compound, Sakura, Staufen,
Germany) on dry ice and 5 μm cryosectionswere prepared for oil red O (ORO) and H&E stain-
ing. ORO staining was carried out with 5 min incubation as described [30]. H&E sections were
stained with Mayer`s Hemalaun for 15 min, 5 min blued, dipped 5x in activated Eosin-G-solu-
tion, drained in an ascending ethanol series and mounted with Roti-Histokit t II. Three sec-
tions per liver as technical replicates were analyzed in bright field with 20x magnification on a
BZ-9000 microscope (Keyence, Neu-Isenburg, Germany) and images were quantified using
ImageJ [31] according to nature protocols [30]. Representative images of each treatment group
are depicted. Scale: black bars represent 50 μm.
mRNA isolation and quantitative real-time PCR
Total RNA was extracted from snap-frozen tissue samples using TRIzol reagent according to
the manufacturer’s protocol. 1 μg RNA was digested with DNase and transcribed into cDNA
via RevertAidReverse Transcriptase. Quantitative real-time PCR was performed on a Lightcy-
cler 480 System (Roche). Relative quantification was performed using the ΔΔct method and
expression data were normalized to Rpl37a gene expression. Following primer sets were used:
Keap1 (Mm00497268_m1), NAD(P)H dehydrogenase, quinone 1 (Nqo1, Mm00500821-m1),
glutamatecysteine ligase, catalytic subunit (Gclc, Mm00802655-m1), glutathione reductase
(Gsr, Mm00439154_m1), NF-E2-related factor 2 (Nrf2, Mm00477784_m1), glutathione
S-transferase A2 (Gsta2, Mm03019257_g1), Gsta4 (Mm004974803_m1), thioredoxin reduc-
tase 1 (Txnrd1, Mm00443675_m1), glutathione S-transferase mu 1 (Gstm1, Mm008339
15_g1), Gstm2 (Mm00725711_s1), Gstm3 (Mm00833923_m1), Gstm4 (Mm00728197_s1),
sulfiredoxin 1 (Srxn1,Mm00769566_m1), microsomal glutathione S-transferase (Mgst3,
Mm00787806_s1), and glutathione peroxidase 2 (Gpx2, Mm00850074_g1), glyceraldehyde-
3-phosphate dehydrogenase (Gapdh, Mm03302249_g1) and ribosomal protein L37a (Rpl37a,
Mm01546394_s1) as TaqMan1 Gene Expression Assay (Thermo Scientific).
Microarray transcript expression profiling
Total RNA was isolated from liver samples of 4 fed and 4 fasted mice for each siRNA group.
The integrity of RNA samples was controlled by RNA nano assay (Agilent 2100 BioAnalyzer)
and transferred to Atlas Biolabs (Berlin) for analysis. Amplification, labeling of probes,
Nrf2 and Liver Metabolism
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AffymetrixGeneChip hybridizations, comparative microarray analysis, and subsequent statis-
tical analysis were performed using Mouse Genome 430 2.0 GeneChips (Affymetrix), as
describedpreviously [21]. All Affymetrixmicroarray data have been deposited in MIAME
compliant format at NCBI-GEO under the accession number GSE80956.
Data and statistical analysis
If not indicated otherwise, all data are presented as mean ± SEM. GraphPad Prism 6 (La Jolla,
USA) was used to calculate all statistics and to draw graphs. Statistical differences were calcu-
lated using one-way or two-way (repeated measurement) ANOVA or Kruskal-Wallis test
depending on whether data passed normal distribution tests adjusted for multiple testing with
Bonferroni’s multiple comparisons test (Bonferroni’s mct) for post hoc analysis where appro-
priate. P values less than 0.05 were considered significant.
Results
Structure, modification and evaluation of two liver-selective
Keap1-specific siRNAs
Recently, we have characterized two siRNAs (Table 1) against murine Keap1, siKeap1-1 and
siKeap1-2, which are able to reduce Keap1 mRNA levels leading to activation of Nrf2 [21]. In
the present study these siRNAs were modified by introducing 2’-O-methyl groups and phos-
phorothioate to allow chronic in vivo administration. The modified siRNAs, siKeap1-1 and
siKeap1-2, showed improved serum stability and a strongly reduced immune stimulatory
potential in relation to the unmodified siRNAs (Table 2), while their potency to suppress
Keap1 expression in mouse hepatoma cells remained unchanged (Fig 1A and 1B). For in vivo
application the siRNAs were formulated with lipid nanoparticles that lead to a targeting of the
oligonucleotidesmainly to hepatocytes [32]. After single i.v. administration both Keap1-speci-
fic siRNAs showed an effective knockdown of hepatic Keap1 mRNA expression, which did not
differ between days 2, 4 and 6 after the application. A modifiednon-silencing scrambled con-
trol siRNA (siControl) did not alter Keap1 inhibition (Fig 1C). At day 6 siKeap1-1 and
siKeap1-2 reduced Keap1 mRNA levels by 85% and 72%, respectively. In order to test,
whether the knockdown of Keap1 led to an activation of Nrf2, the expression levels of the Nrf2
target gene Nqo1 (NAD(P)H quinone oxidoreductase 1) were determined.Hepatic Nqo1 tran-
script levels were elevated at day 2, 4 and 6 after either siKeap1-1 or siKeap1-2 injection with
a 4.5- and 3.2-fold increase, respectively, at day 6 (Fig 1D). From this data it was concluded
that a once weekly i.v. injection of either siKeap1-1 or siKeap1-2 was sufficient to both reduce
Keap1 expression and to stimulate Nrf2-related gene expression in vivo. In a second pilot
study, mice were fed either a WD or a normal chow diet (ND) for over 20 weeks. Neither a
reduction of Keap1 mRNA expression nor an induction of Nrf2 or its target genes Gclc and
Nqo1 could by observed in theWD group compared to the ND group (Fig 1E). Therefore, we
did not include a ND control group in our chronic siRNA study.
Gene expression analysis after chronic suppression of Keap1
In order to study the effect of chronic Keap1 knockdown, body weight-matched mice on a WD
were treated once weekly with either siKeap1-1, siKeap1-2 or siControl for 7 weeks (Fig 2A).
At the end of the experimentmRNA levels of Keap1 and selectedNrf2-target genes levels were
determined in liver, skeletal muscle and kidney by RT-qPCR (Fig 2B–2D). After 7 weeks of
intervention the hepatic Keap1 mRNA was significantly reduced by 88% and 80% for siKeap1-
1 and siKeap1-2 siRNA, respectively (Fig 2B). The expression of the Nrf2-target gene Nqo1
Nrf2 and Liver Metabolism
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increased 10.3- and 6.8-fold in response to siKeap1-1 and siKeap1-2, respectively. In addition,
the Nrf2-target genes glutathione reductase (Gsr) and glutamate cysteine ligase catalytic subunit
(Gclc) were upregulated 2- and 1.8 fold as well as 3.4- and 2.7-fold for siKeap1-1 and siKeap1-
2, respectively. Neither siKeap1-1 nor siKeap1-2 influenced the expression of Keap1 or Nqo1
in muscle (Fig 2C). In the kidney siKeap1-1 and siKeap1-2 reduced the expression of Keap1 by
58% and 57% for siKeap1-1 and siKeap1-2, respectively (Fig 2D). However, Nqo1 expression
Fig 1. In vitro and in vivo validation of Keap1 knockdown by Keap1-specific siRNAs. (A-B) Dose-response curves
upon transfection of Hepa1c1c7 cells with Keap1-specific siRNA molecules. Relative Keap1 expression inhibited by (A) the
modified siKeap1-1* siRNA and its unmodified form (siKeap1-1) and (B) the modified siKeap1-2* siRNA and its unmodified
form (siKeap1-2) (n = 2). (C-D) Gene expression of (C) Keap1 and (D) a Nrf2 target gene Nqo1 in mouse liver 2, 4 and 6
days after siRNA injection for a pilot study (n = 3). (E) Regulation of Keap1, Nrf2 and its target genes Gclc and Nqo1 in liver
of mice fed either a normal chow diet (ND) or a Western diet (WD) for 20 weeks (n = 6). Data are represented as
mean ± SEM. &: siRNA vs. siControl* p < 0.05, §: siRNA vs. siControl* p < 0.01, #: siRNA vs. siControl* p < 0.001. Two-
way ANOVA with Bonferroni’s mct. siKeap1-1* and siKeap1-2*: modified Keap1-specific siRNAs, siControl*: modified
scrambled unspecific control siRNA.
doi:10.1371/journal.pone.0166110.g001
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was not upregulated indicating that Nrf2-signalingwas not significantly activated in kidney.
Overall, the data suggest that the chronic administration of either siKeap1-1 or siKeap1-2
caused a regulation of Keap1 and Nrf2 target genes predominantly in liver.
Whole genome expression analysis revealed that the chronic suppression of Keap1 by
siKeap1-1 and siKeap1-2 regulated 269 and 252 probe sets, respectively, in relation to
siControl (S1 and S2 Tables). 160 probe sets were regulated by both siKeap1-1 and siKeap1-
2 (Fig 3A and S3 Table). Mapping of this core set of probe sets regulated by both siRNAs to
Fig 2. Keap1 inhibition and Nrf2 target gene regulation by liver-selective, Keap1-specific siRNAs in mice after siRNA and
WD intervention. (A) Schematic of the long-term mouse experiment. (B) Hepatic Keap1 as well as Nrf2 target genes Nqo1, Gclc
and Gsr expression (n = 11). (C) Relative mRNA expression of Keap1 and Nqo1 in muscle tissue of mice (fed, n = 6). (D)
Expression levels of Keap1 and Nqo1 in kidney (fed, n = 6,). Data are represented as mean ± SEM. One-way ANOVA with
Bonferroni’s mct. ** p < 0.01, *** p < 0.001. Black arrows: Recording of body weight and siRNA injection, Grey arrows:
Experimental procedures: BC: Analysis of body composition by 1H-nuclear magnetic resonance, EX: Sacrificing mice and organ
preparation, ipGTT: intraperitoneal glucose tolerance test, MCA: Metabolic cage analysis.
doi:10.1371/journal.pone.0166110.g002
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canonical pathways revealed the activation of pathways that are linked to cytoprotection and
metabolismof xenobiotics (Table 3). The majority of these genes upregulated by both Keap1-spe-
cific siRNAs were also examined by quantitative real-time PCR to confirm the whole genome
expression analysis and, therefore, the induction of Nrf2 target genes in the different oxidative
stress response pathways (Fig 3B–3D) These pathways are characteristic for Nrf2 signaling [3, 33]
and demonstrated that both siKeap1-1 and siKeap1-2 activated Nrf2 signaling chronically in
liver. As metabolic pathway, only canonical cholesterol synthesis was down-regulated by both siR-
NAs against Keap1 (Table 3). Neither the core set of probe sets regulated by both siRNAs nor
those that were regulated by only one of the siRNAs included any genes encoding proteins known
to be involved in fatty acid- and glucose-handling (S1 and S2 Tables). Altogether, the gene expres-
sion data showed that the chronic administration of either siKeap1-1 or siKeap1-2 suppressed
hepatic Keap1 expression and stimulated Nrf2-signaling in liver, but had no effect on genes
encoding proteins that are involved in the metabolism of either fatty acids or carbohydrates.
Chronic hepatic Keap1 knockdown affected neither body composition,
weight gain nor the metabolic profile
The effects of Keap1 suppression and the subsequent regulation of Nrf2 target genes on body
composition were assessed at day 0 and in weeks 5 and 7 before sacrificing (S4 Table).
Fig 3. Overlap of probe sets regulated by siKeap1-1* and siKeap1-2* and verification of upregulated genes by
quantitative real-time PCR. (A) Venn diagram of analyzed genes that were regulated by the administration of either
siKeap1-1* or siKeap1-2* in relation to non-silencing siControl* (fold-change >2, two-way ANOVA p < 0.01, n = 8). (B-D)
Relative gene expression of upregulated genes under siKeap1-1* and siKeap1-2* treatment in liver of mice (fed, n = 6).
Data are represented as mean ± SEM. One-way ANOVA with Bonferroni’s mct. * p < 0.05, ** p < 0.01, *** p < 0.001.
doi:10.1371/journal.pone.0166110.g003
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Treatment with neither siKeap1-2 nor siKeap1-2 affected lean bodymass, free body fluids,
body-fat content and weight gain relative to siControl (Fig 4A–4D). Absolute body weight
gain was slightly increased 1.2-fold in the siKeap1-1 group relative to siControl; siKeap1-2
had no significant effect (Fig 4E). Hepatic Keap1 suppression influencedneither whole-body
fat accumulation nor weight gain.
A metabolic cage study was performed after 5 weeks of intervention. Neither siKeap1-1
nor siKeap1-2 affected food and water intake over 24 h (Fig 5A and 5B). The total caloric
intake combined from the HFD and the 6% sucrose in the drinkingwater was comparable
(Table 4). Furthermore, the locomotor activity during day and night time followed natural hab-
its with a rapid increase at onset of dark phase and was similar between all groups (Fig 5C).
The oxygen consumption (VO2) and the according carbon dioxide production (VCO2) showed
no differences between the treatment groups in relation to animals treated with siControl (Fig
5D and Table 4). In addition, the energy expenditure (EE) adjusted on lean bodymass and the
respiratory exchange ratio (RER), as ratio of VCO2 and VO2, revealed no effect of reduced
Keap1 expression on basal metabolism (Fig 5E and 5F). Also in week 5 an ipGTTwas per-
formed in order to assess a potential impact of hepatic Keap1 knockdown on glucose homeo-
stasis. The administration of either siKeap1-1 or siKeap1-2 revealed no effect on glucose
tolerance (Fig 5G).
After the treatment with siKeap1-1, but not with siKeap1-2 the liver / body weight ratio
and the liver weight of fed animals were slightly elevated (Fig 6A and 6B). Epididymal WAT
weight was slightly increased by siKeap1-1. Neither siKeap1-1 nor siKeap1-2 influenced sig-
nificantly plasma glucose levels, insulin or NEFA levels in the fed or fasted state (Fig 6C). HDL
and LDL levels were also not significantly different between the treatment groups (Fig 6D).
Additionally, concentrations of the liver enzymes AST (aspartate transaminase) and ALT (ala-
nine transaminase) were also measured in serumof fed mice. However, no evidence for
increased hepatic inflammationmediated by either theWD or hepatotoxicity induced due to
the siRNA administration was revealed (Fig 6E). The administration of siKeap1-1 slightly ele-
vated plasma levels of triglycerides and cholesterol in fed state (Fig 6F). Neither siKeap1-1 nor
siKeap1-2 affected hepatic lipids (Fig 6G). As we observed an increased liver weight and
plasma triglyceride content but no elevated triglyceride levels in liver of siKeap1-1 treated
mice, we additionally analyzed the hepatic glycogen content of fed mice. The glycogen concen-
tration in the liver was again significantly increased under siKeap1-1 but only slightly elevated
under siKeap1-2 siRNA treatment (Fig 6H). Therefore, we analyzed liver sections of fed mice
by Oil Red O (ORO) staining to further verify the hepatic content of neutral lipids. However,
we did not observe an altered amount or a modified size of lipid droplets in either




Glutathione-mediated detoxification 8.1 Gsta1, Gsta2, Gsta4, Gstm1, Gstm2, Gstm3, Gstm4, Mgst3
Nrf2-mediated oxidative stress
response
8.0 Gpx2, Gclc, Nqo1, Txnrd1, Srxn1
Superpathway of cholesterol
biosynthesis
5.4 Hmgcr, Lss, Sc5d, Fads1, Fdps, Sc5d
Xenobiotic metabolism pathway 5.2 Cyp2b9, Cyp2b10, Cyp2g1, Cyp2a4, Gsta1, Gsta2, Gsta4, Gstm1, Gstm2, Gstm3,
Gstm4, Mgst3
Genes significantly regulated in liver of mice by silencing Keap1 expression by two different Keap1-specific siRNAs versus siControl* were mapped by
Ingenuity Pathway Analysis. The significance of the pathway is given as -log p value (Fisher’s exact test).
doi:10.1371/journal.pone.0166110.t003
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Keap1-specific siRNA group compared to the control group (Fig 7A). The densitometric quan-
tification of neutral lipids stained by ORO showed also no significant differences between each
group (Fig 7B) In a last step, we monitored liver morphology using H&E stainings and did not
reveal obvious pathological morbidities in liver tissues of any treatment group (Fig 7C).
Considering the number of endpoints analyzed, we found no conclusive differences on any
of the investigated metabolic traits.
Discussion
In this study we investigated the effects of chronic activation of Nrf2 signaling in liver on gene
expression and metabolic parameters in mice fed on a WD for 7 weeks. Nrf2 signaling was
Fig 4. Body composition of mice during 7 weeks of WD and siRNA intervention. (A) Lean body mass, (B) free fluid
and (C) fat body mass at beginning (0 weeks), in week 5 and at end of intervention (week 7) of mice treated with control and
both Keap1-specific siRNAs. (D) Development of body weight under specific diet within 7 weeks. (E) Absolute body weight
gain of each treatment group (* p = 0.015, one-way ANOVA with Bonferroni’s mct). Data are represented as mean ± SEM.
n = 11.
doi:10.1371/journal.pone.0166110.g004
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Fig 5. Metabolic characterization of siRNA-treated mice. (A-F) 24 h average of metabolic cage analysis during light and
dark phase of (A) food intake, (B) water consumption supplemented with 6% sucrose, (C) locomotor activity, (D) oxygen
consumption rate, (E) energy expenditure and (F) respiratory exchange ratio (VCO2/VO2). (siControl* n = 9, siKeap1-1*
n = 9 and siKeap1-2* n = 10). (G) Blood glucose levels (glucose: 1 mg/kg BW) during ipGTT (n = 11). Data are represented
as mean ± SEM. Grey background in graphs indicates dark phase.
doi:10.1371/journal.pone.0166110.g005
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activated by the suppression of Keap1 as describedpreviously [22]. Here, we used two different
liver-selective siRNAs against Keap1 in order to reduce the risk of unspecific off-target effects.
In liver, the target organ of the modified siRNAs, a strong suppression of Keap1 expression
was accomplished by both Keap1-specific siRNAs and subsequent activation of Nrf2 target
genes was observed in liver but not in kidney. Notably, we observed a slight yet significant
downregulation of Keap1 mRNA in kidney of siKeap1-1 and siKeap1-2-treated mice. This
did not result in a significant upregulation of the prototypical Nrf2 target gene Nqo1, most
likely due to the relatively moderate downregulation of Keap1 in kidney.
Whole genome expression analysis and canonical pathway mapping proved the regulation
of canonical Nrf2 signaling in liver by the siRNAs. As expected genes involved in antioxidative
stress response and xenobiotic metabolismwere induced by the suppression of Keap1. This is
in line with a previous report using a constitutive model of Keap1 suppression [33]. However,
neither genes involved in the metabolism of fatty acids nor of carbohydrates were regulated by
the activation of Nrf2. In line with our gene expression results we could not detect alterations
of metabolic parameters such as hepatic and serum triglyceride levels or glucose tolerance.
Interestingly, we observed a suppression of genes involved in the synthesis of cholesterol,
although both plasma and hepatic cholesterol levels were unchanged. As the inhibition of cho-
lesterol synthesis by e.g. statins has only a minor effect in mice, future studies will have to
investigate more appropriate animal models of cholesterol metabolism, such as guinea pigs, in
order to elucidate the potential of Nrf2 activation in the regulation of cholesterol levels.
Although the effects of siKeap1-1 and siKeap1-2 were similar, they slightly differed with
respect to their action on weight gain and the liver / body weight ratio in the fed state as well as
hepatic triglyceride and glycogen content which were expected to be reduced under Keap-
1-specific siRNA treatment. It is unclear, if these discrepancies are due to either off-target
effects or to the slightly higher suppression of Keap1 expression by siKeap1-1. However, in
the latter case the increased body weight gain does also not indicate that increased activation of
Nrf2 is a viable approach for the treatment of metabolic disease.Our data differ from some pre-
vious publications, in which metabolic effects as well as changes in the gene expression of e.g.
fatty acid synthase 1, stearoyl-CoA desaturase 1, acetyl-CoA carboxylase and glucose 6-phos-
phatase catalytic subunit were described after genetic or pharmacological activation of Nrf2
[6–8, 11, 16, 34–36]. The pharmacological small-moleculeNrf2 activators such as CDDO and
Oltipraz have been associated with toxicity in chronic studies [9, 10], which will impact inter-
mediarymetabolism and could be a confounding factor in previous studies. Major differences
between our studies and previous genetic models are the timing and tissue selectivity of the
genetic activation of Nrf2. Previously, the effects of genetic Nrf2 activation were studied in
floxed Keap1 mice [16, 35–37], making use of the hypomorphic character of the floxed allele,
which leads to a constitutive expression of Nrf2 in multiple tissues [38]. The hepatocyte-spe-
cific Keap1 knockout animals used in [11] were generated by breeding these Keap1 floxedmice
Table 4. Basal metabolic characterization of siRNA-treated mice.
siRNA siControl* siKeap1-1* siKeap1-2*
Locomotor activity (counts/h) 1721 ± 132 1983 ± 137 1770 ± 95
Oxygen consumption (ml/kg/h)A 5613 ± 104 5505 ± 125 5832 ± 127
Carbon dioxide production (ml/kg/h)A 4213 ± 62 4083 ± 73 4321 ± 92
Energy expenditure (kcal/kg/h)A 26.8 ± 0.5 26.2 ± 0.6 27.8 ± 0.6
Total caloric intake (kcal/kg/h) 29.2 ± 4.0 29.1 ± 2.9 26.9 ± 3.5
Mice fed a WD and received a liver-selective siRNA treatment. Data are represented as mean ± SEM. n = 9/9/10. Avalues calculated on lean body mass.
doi:10.1371/journal.pone.0166110.t004
Nrf2 and Liver Metabolism
PLOS ONE | DOI:10.1371/journal.pone.0166110 November 4, 2016 13 / 19
Fig 6. Plasma and hepatic parameter of mice either fed or fasted for 16 h under specific siRNA treatment. (A) Ratio
of liver weight to body weight. (B) Weight of liver and epididymal (e), perirenal (p) and subcutaneous (s) white adipose
tissue (WAT). (C) Basal blood glucose, insulin and non-esterified fatty acids (NEFA) concentration. (D) Plasma levels of
HDL and LDL cholesterol. (E) Concentration of enzymes AST (aspartate transaminase) and ALT (alanine transaminase) in
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with albumin-Cre transgenic mice. [38]. With it in previous genetic models the effects of a life-
long, whole-body activation of Nrf2 were studied. In contrast, we activated Nrf2 expression in
liver of adult mice using siRNAs. This approach eliminates potential developmental conse-
quences of the constitutive, whole-body activation of Nrf2 expression. We believe that our
approach to activate Nrf2 in adult animals may more appropriately reflect the therapeutic situ-
ation and the lack of effects under those conditions raises doubts whether hepatic Nrf2 activa-
tion is a feasible therapeutic target.
In our study, mice were fed a WD for 7 weeks.We found no evidence that HFD/WD per se
induces oxidative stress or an induction of Nrf2. This was demonstrated in a pilot study feeding
mice either a normal chow diet (ND) or a WD over 20 weeks.Within that study we did not
observe a downregulation of Keap1 nor an upregulation of Nrf2 or its target genes Nqo1 or
Gclc inWD-fed compared to ND. Therefore we did not include a ND group in our chronic
study. However, under certain artificial dietary conditions (such as a methionine- and choline-
deficient diet) pronounced oxidative or inflammatory stress might have been induced which
could stimulate Nrf2. TheWD showed only a mild increase in body weight gain and liver lipids
(e.g. triglycerides, glycogen, neutral lipids, ORO stainings) in all treatment groups and both
Keap1-specific siRNAs showed no consistent benefit of siRNA treatment onWD feeding. In
contrast to our expectations, we did not observe a decrease in weight gain or hepatic triglycer-
ide accumulation.We cannot exclude that the activation of Nrf2 in a model of increased
serum of fed mice. (F-G) Triglyceride, cholesterol and phospholipid concentration in (F) plasma and (G) liver lysates. (H)
Glycogen concentration in liver tissue of fed mice. Data are represented as mean ± SEM. Fed: n = 6, fasted: n = 5. Two-way
ANOVA with Bonferroni’s mct. * p < 0.05, *** p < 0.001.
doi:10.1371/journal.pone.0166110.g006
Fig 7. Oil Red O (ORO) and H&E stainings of fed mice treated with Keap1-specific siRNAs. (A) Neutral lipids stained
by ORO in liver section. (B) Quantification of ORO stainings by densitometric analysis (fed, n = 6). (C) H&E staining of liver
sections. Representative images are depicted in A and C. Data represent mean ± SEM. n = 6. Black scales indicate 50 μm.
doi:10.1371/journal.pone.0166110.g007
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oxidative stress may have indirect metabolic effects through the activation of anti-inflamma-
tory or antioxidative pathways.
In summary, our results show that the chronic suppression of Keap1 expression in liver
stimulates Nrf2 target genes involved in antioxidative stress response and xenobiotic metabo-
lism, but has no significant effect on hepatic lipid and glucosemetabolism in mice fed a WD.
Hence, beneficial effects on glucosemetabolism and lipid handling reported by others may
result from an extra-hepatic, not liver-intrinsic Nrf2 activation [6–8, 11, 34–36]. With that we
found no evidence that the activation of hepatic Nrf2 could be a target for the treatment of fea-
tures of metabolic diseases, such as hepatic insulin resistance or steatosis.
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